<DOC>
	<DOC>NCT02449044</DOC>
	<brief_summary>This study will assess the safety of long-term tolvaptan use in patients previously enrolled in shorter-term Phase 3 studies and gather information on the natural history of hyponatremia in the context of tolvaptan therapy and underlying disease states.</brief_summary>
	<brief_title>International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1. Age greater than or equal to 18 years. 2. Ability to provide informed consent or assent. 3. Prior successful participation in a tolvaptan hyponatremia trial termination with evidence of continued need or desire for therapy. A current medical condition where longterm treatment with an aquaretic agent may present an undue risk to the patient. Hyponatremia which is acute, reversible, artifactual or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy. Hyponatremia due to reversible medical condition or therapy Conditions associated with an independent imminent risk of morbidity and mortality Conditions which confound the assessment of endpoints.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Hyponatremia</keyword>
</DOC>